Model Medicines
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Platform for Therapeutics
Model Medicines is an AI-first biotechnology company that uses a proprietary discovery engine to systematically identify conserved biological choke points and design precision therapeutics against them. Our proprietary GALILEO™ platform powers end-to-end target discovery, drug discovery, and development, validated by 67 compounds across 12 targets, with two IND-track programs. MDL-001 targets the RdRp Thumb-1 site, a conserved choke point in viral replication, with potent activity across Influenza A/B, Coronaviruses, RSV, HCV, HBV, HDV, and their co-infections from a single oral molecule, advancing toward IND in 2026. MDL-4102 targets BRD4, a master regulator of transcriptional control, advancing across fibrosis, immunology, cardiovascular, and oncology indications, with IND targeted for 2027. Each program has multiple follow-on assets in corresponding indications. Recognized in Fierce 15, GEN's Ten Companies to Watch in AI Drug Discovery, and the BARDA Vanguard Program.
Company HQ City:
San Diego
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2019
Lead Product in Development:
MDL-001 is a first-in-class, oral, non-nucleoside, direct-acting broad-spectrum antiviral targeting the RdRp Thumb-1 cryptic site, a highly conserved allosteric choke point in viral RNA-dependent RNA polymerase shared across positive-sense single-stranded RNA viruses. The single molecule demonstrates potent antiviral activity across six viral families: HCV, HBV, HDV, SARS-CoV-2, Influenza A/B, and RSV, including clinically challenging co-infections (HCV/HBV, HBV/HDV). IND submission is targeting late 2026. U.S. Patent 12,551,475 B2 granted.
CEO
Daniel Haders PhD
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
Two lead assets.
MDL-001 — First-in-class, oral, non-nucleoside, direct-acting broad-spectrum antiviral targeting the RdRp Thumb-1 cryptic site, a conserved choke point in viral replication. Single molecule with potent activity across HCV, HBV, HDV, SARS-CoV-2, Influenza A/B, and RSV, including co-infections. IND targeting late 2026.
MDL-4102 — First-in-class, oral, selective BRD4 inhibitor with no measurable activity against BRD2 or BRD3, targeting a master regulator of transcriptional control. Designed to overcome the dose-limiting thrombocytopenia that hindered prior pan-BET inhibitors. Indications span fibrosis, immunology & inflammation, cardiovascular, and oncology. IND targeting 2027.
When you expect your next catalyst update?
December 2026
What is your next catalyst (value inflection) update?
MDL-001 IND submission targeting late 2026, with clinical trials estimated to commence early 2027. MDL-4102 IND submission targeting 2027. 1-trillion-compound GALILEO™ virtual screen targeting late 2026, following the record 325-billion-compound screen completed in 2025.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}